期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PIRH2在肾细胞癌中的表达及其意义 被引量：2

Expression and clinical significance of PIRH2 in renal cell carcinoma
下载PDF
导出
摘要 目的检测PIRH2蛋白在肾细胞癌中的表达,探讨其与临床病理特征间的关系。方法利用免疫组化SP法分别检测肾癌及对应癌旁正常肾组织(各56例)中PIRH2的表达情况,以软件SPSS 17.0进行统计分析。结果 PIRH2在肾癌组织和癌旁正常肾组织中的阳性表达率分别为55.4%和16.1%,差异有统计学意义(P<0.05)。肾癌中PIRH2的高表达与临床分期、病理分化程度有关(P<0.05),而与病理类型、性别、年龄等无关(P>0.05)。结论 PIRH2可能参与了肾癌的发生发展过程,靶向抑制PIRH2表达有望成为晚期肾癌治疗的新方法。 Objective To investigate the expression level and clinical significance of p53-induced RING-H2 protein （PIRH2） in renal cell carcinoma （RCC）. Methods Expression of PIRH2 protein was analyzed by immunohistochemistry in 56 RCC cancer tissues and their adjacent normal renal tissues. Results Immunohistochemistry analysis revealed that the positive rate of PIRH2 in RCC tissues was significant higher than that of in normal tissues （55.4% versus 16.1 %）. Over expression of PIRH2 was associated with the clinical stage, pathological differentiation while were not correlated with pathological types, age and gender （P〉0.05）. Conclusion Dysregulated expression of PIRH2 may play important roles in kidney carcinogenesis and progression. Inhibition of PIRH2 is a promising therapeutic approach for RCC.
作者 王国栋 党亚正
机构地区 解放军第三二三医院综合内科
出处 《西部医学》 2014年第3期280-282,共3页 Medical Journal of West China
基金 陕西省自然科学基金(CWS105B07)
关键词 肾细胞癌 PIRH2 免疫组织化学 Renal cell earcinoma PIRH2, Immunohistochemistry
分类号 R737.11 [医药卫生—肿瘤] R446.8 [医药卫生—诊断学]
  • 相关文献

参考文献11

  • 1Jemal A,Siegel R,Xu J. Cancer statistics,2010[J].CA-A Cancer Journal for Clinicians,2010.277-300.
  • 2邱艳艳,董兰兰,朱果果,刘永娟,何小华,刘万红.泛素连接酶Pirh2与恶性肿瘤相关性的研究进展[J].肿瘤,2011,31(4):369-373. 被引量：6
  • 3Hong Wu,Zeinab Rami Abou,Elsa RF. PIRH2,a Ubiquitin E3 Ligase,Inhibits p73 Transcriptional Activity by Promoting Its Ubiquitination[J].Molecular Cancer Research,2011.1780-1790.
  • 4Yong-Sam Jung,Yingjuan Qian,Xinbin Chen. The p73 Tumor Suppressor Is Targeted by PIRH2 RING Finger E3 Ubiquitin Ligase for the Proteasome-dependent Degradation[J].The Journal of Biological Chemistry,2011,(41):35388-35395.
  • 5Bohgaki M,Hakem A,Halaby MJ. The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover[J].CELL DEATH AND DIFFERENTIATION,2013.812-822.
  • 6HoellerD,Hecker CM,Dikeic I. Ubiquitin and ubiquitinlike proteins in cancer pathogenesis[J].Nature Reviews Cancer,2005,(10):776-788.
  • 7Yong-Sam Jung,Yingjuan Qian,Xinbin Chen. PIRH2 RING-finger E3 ubiquitin ligase:its role in tumorigenesis and cancer therapy[J].FEBS Letters,2012,(10):1397-1402.
  • 8Zhihao wang,Bo Yang,Lanlan Dong. A novel oncoprotein PIRH2:rising from the shadow of MDM2[J].CANCER SCIENCE,2011,(05):909-917.
  • 9Anne Hakem,Miyuki Bohgaki,Benedicte Lemmers. role of pirh2 in mediating the regulation of p53 and c-myc[J].PLoS Genetics,2011,(11):e1002360.
  • 10Liang Hu,Ming Liu,Leilei Chen. SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of PIRH2 and has tumor-suppressive function in the development of hepatocellular carcinoma[J].CARCINOGENESIS,2012,(08):1581-1588.

二级参考文献33

  • 1秦维香,张晓艳,刘东举,谢成耀.增殖细胞核抗原和P27在前列腺癌中的表达及临床意义[J].中国医院用药评价与分析,2007,7(1):50-52. 被引量：4
  • 2DUAN S,YAO Z,ZHU Y,et al.The Pirh2-keratin 8/18 interaction modulates the cellular distribution of mitochondria and UV-induced apoptosis[J].Cell Death Differ,2009,16(6):826-837.
  • 3KOIVUSALO R,KRAUSZ E,HELENIUS H,et al.Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA:opposite effect of siRNA in combination with different drugs[J] ,Mol Pharmacol,2005,68(2):372-382.
  • 4KOIVUSLO R,MIALON A,PITKANEN H,et al.Activation of p53 in cervical cancer cells by human papillomavirus E6 RNA interference is transient,but can be sustained by inhibiting endogenous nuclear export-dependent p53 antagonists[J].Cancer Res,2006,66(24):11817-11824.
  • 5SHIMADA M,KITAGAWA K,DOBASHI Y,et al,High expression of Pirh2,an E3 ligase for p27,is associated with low expression of p27 and poor prognosis in head and neck cancers[J].Cancer Sci,2009,100(5):866-872.
  • 6WANG X M,YANG L Y,GUO L,et al.p53-induced RING-H2 protein,a novel marker for poor survival in hepatocellular carcinoma after hepatic resection[J].Cancer Sci,2009,115(19):4554-4563.
  • 7PARK J H,KOH K C,CHOI M S,et al.Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma[J].Am J Surg,2006,192(1):29-33.
  • 8SUH K S,CHO E H,LEE H W,et al.Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria[J].Dig Dis,2007,25(4):329-333.
  • 9KIM B K,HAN K H,PARK Y N,et al.Prediction of microvascular invasion before curative resection of hepatocellular carcinoma[J].J Surg Oncol,2008,97(3):246-252.
  • 10SHIRABE K,WAKIYANMA S,GION T,et al.Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma-results of 152 resected cases[J].Hepatogastroenterology,2007,54(79):2084-2087.

共引文献5

同被引文献24

引证文献2

二级引证文献48

西部医学
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部